Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) (Address of principal executi ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results Net income of $1.5 million Adjusted EBITDA1 of $1.9 million ADHD Portfolio net revenue up 1% to $15.3 million Pediatric Portfolio net revenue up 54% sequentially $20.1 million cash balance at September 30, 2024 Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow Ryan Selhorn promoted to Chief Financial Of ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] Please note this conference is being recorded. I will n ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital Market Securities registered pursu ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business TTM March 2024 companywide adjusted EBITDA of positive $15.4 million TTM March 2024 adjusted EBITDA of positive $17.1 million for the Rx Business $19.8 million cash balance at March 31, 2024 Company to host conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File No. 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 47-0883144 (State or other j ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Conference Call February 14, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2024 Q2 Earnings Call. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Roger Weiss. You may begin. R ...